Skip to content
Sectors How it works Pricing Client stories

Insights

Companies Live signals Events Markets Trends Company lists
Log in
Platform Signal Tracker API Radar Book a 7-day Readout
Corteria Pharmaceuticals logo — Interceptive therapies for the treatment of heart failure su...

Corteria Pharmaceuticals

Interceptive therapies for the treatment of heart failure subpopulations

Founded 2021 France France 24 employees Series A Total: $77.00M Biotechnology, Health and Wellness +1

General Information

Company Name Corteria Pharmaceuticals
Founded Year 2021
Location France France
Employees 24
Industries Biotechnology, Health and Wellness, Pharmaceutical
Funding Stage Series A
Business Model B2B, B2D
Revenue Model Licensing, Product Sales
Social

BounceWatch is an independent company data service, not affiliated with Corteria Pharmaceuticals. To contact Corteria Pharmaceuticals, visit corteriapharma.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Corteria Pharmaceuticals compare?

A PDF of Corteria Pharmaceuticals and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Corteria Pharmaceuticals soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About Corteria Pharmaceuticals

Corteria Pharmaceuticals, founded in 2021, is a France-based biotechnology company focused on developing transformative interceptive therapies specifically tailored for treating subpopulations experiencing worsening and acute decompensated heart failure. Situated at the intersection of the Biotechnology, Health and Wellness, and Pharmaceutical industries, the company's strategic focus addresses critical unmet needs in heart failure management.

Recently, Corteria Pharmaceuticals secured a significant €65.00M Series A investment on 07 September 2023. This infusion was led by a consortium of influential investors including Kurma Partners, Omnes Capital, OrbiMed, Fountain Healthcare Partners, Jeito Capital, V-Bio Ventures, and Invivo Capital Partners. This strong backing underscores investor confidence in Corteria's niche approach and potential for substantial impact in the cardiovascular therapeutic space.

Business keywords: heart failure treatment, pharmaceutical development, first-in-class drugs, subpopulation targeting, transformative therapies, worsening heart failure, acute decompensated heart failure

Services & Products

Development of first-in-class drugs
Targeted therapies for high unmet medical needs
Clinical trial management
Patient stratification methodology

Target Customers

Patients with heart failure Patients with sarcopenia Patients with obesity and related complications Healthcare providers

Funding Rounds & Investors (2)

View All
Funding Stage Amount Investors Lead Investors Date
Series A €65.00M 7
Kurma Partners Omnes Capital OrbiMed
Kurma Partners, Omnes Capital +5
01 Sep 2023
Seed €12.00M 4
Kurma Partners Omnes Capital V-Bio Ventures
Kurma Partners, Omnes Capital +2
01 Dec 2021

Corteria Pharmaceuticals Alternatives & Competitors

View All Alternatives
Corteria Pharmaceuticals vs
Ultragenyx
Ultragenyx United States

Going Beyond Every Day

Post-IPO Equity
1535 employees
Biotechnology, Health Care
Corteria Pharmaceuticals vs
Biogen
Biogen United States

Innovative therapies worldwide for people living with serious neurological and neurodegenerative dis...

IPO
7823 employees
Biotechnology, Health Care
Corteria Pharmaceuticals vs
Kite Pharma
Kite Pharma United States

At Kite, a Gilead Company, our singular focus is cell therapy to treat and cure cancer.

Acquired
4013 employees
Biotechnology, Health Care
View all alternatives

FAQ About Corteria Pharmaceuticals

Interceptive therapies for the treatment of heart failure subpopulations
Corteria Pharmaceuticals was founded in 2021.
Corteria Pharmaceuticals is headquartered in France.
Corteria Pharmaceuticals operates in Biotechnology, Health and Wellness and Pharmaceutical. Its work centres on heart failure treatment, pharmaceutical development, first-in-class drugs and subpopulation targeting. Its customers include Patients with heart failure, Patients with sarcopenia and Patients with obesity and related complications.
Corteria Pharmaceuticals has a B2B and B2D business model. Its revenue comes from Licensing and Product Sales.
Corteria Pharmaceuticals has approximately 24 employees.
Corteria Pharmaceuticals has completed 2 funding rounds, raising a total of $77.00M. The latest funding stage is Series A.
Corteria Pharmaceuticals offers: Development of first-in-class drugs, Targeted therapies for high unmet medical needs, Clinical trial management, Patient stratification methodology.
Top alternatives and competitors to Corteria Pharmaceuticals include Ultragenyx, Biogen, Kite Pharma, Skye Bioscience Inc., Heartseed Inc.. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Corteria Pharmaceuticals and Ultragenyx are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Corteria Pharmaceuticals, https://bouncewatch.com/company/corteria-pharmaceuticals, updated 28 January 2026. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Talk to an analyst Book a 7-day Readout